Alan Tan, MD, discusses upcoming trials that could change the landscape of frontline and adjuvant renal cell carcinoma ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma InterestProvidence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean ...

Panelists discuss how successful transitions between Bruton tyrosine kinase (BTK) inhibitors require careful management of ...

Researchers at McMaster University have made a discovery in the field of hematology, providing an explanation for spontaneous ...

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in untreated MCL ...

Pharmaceutical ads are difficult to avoid in American television programming and a growing number of them promote a class of ...

TheraBionic is the only FDA-approved therapy indicated in liver cancer patients that fail first-line and second-line therapy, so that's really the place it takes right now in 2025. Patients can ...

Disparate pathogenic mechanisms complicate precision-medicine efforts to treat diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis. Though potentially curable with frontline ...